Zealand Pharma A/S (ZLDPF) – What Are Analysts Thinking About This Stock?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been given a consensus rating of “Hold” by the eleven brokerages that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company.

ZLDPF has been the topic of several analyst reports. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Finally, Zacks Research raised Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th.

Zealand Pharma A/S Price Performance

ZLDPF opened at $33.88 on Tuesday. The firm has a market capitalization of $2.42 billion, a PE ratio of 5.62 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. The business’s 50-day moving average is $42.68 and its two-hundred day moving average is $45.54. Zealand Pharma A/S has a 1 year low of $33.39 and a 1 year high of $83.12.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.

Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.